Skip to main content
. 2020 May 28;12(6):1393. doi: 10.3390/cancers12061393

Figure 5.

Figure 5

EGF is the factor in CAF CMtx conferring cetuximab resistance in cancer cells. (A) DiFi cells were treated with various cetuximab concentrations while cultured in Dulbecco’s Modified Eagle Media (DMEM), 13000CMtx, or 13000CMtx-EGF (i.e., 13000CMtx treated with anti-EGF) media. Images were acquired on days 0, 3, and 5, and representative images from day five are shown. (B) Live and dead cell counts were obtained and fitted to an exponential growth model to calculate the growth rate. (C) DiFi cells were cultured with CMtx or CMtx-EGF collected from CAF12905, CAF12911, and CAF13000 with or without 1 µg/mL cetuximab. Growth rates were calculated and the absolute difference (treated-untreated) is shown. (D) Conditioned media was collected from CAF12905 treated with 1 µg/mL cetuximab (12905CMtx) in fetal bovine serum (FBS)-free media. Following overnight serum-starving, DiFi cells were cultured with 1 µg/mL cetuximab and/or 12905CMtx for 2 h. Protein expression was evaluated via western blot. p-value ≤ 0.01: **; p-value ≤ 0.05: *.